From the NEW Reuters Report on CLL (April 10/2008).
Much lower then my numbers ($0.5 to $0.6 cash flow per share). I always thought that I know much more on CLL numbers then average institutional analyst and my estimates were much more accurate then theirs. What am I missing here?
JUREK
Consensus Estimates Analysts (3 analysts)
Sales (Millions)
Year Ending Dec 08: $480.8
Year Ending Dec 09: $551.7
Earnings (Per share)
Year Ending Dec 08 : $0.2 (by 3 analyst)
Year Ending Dec 09: $0.2 (by 2 analyst)
Profit (loses) (Millions)
Year Ending Dec 08: ($85.2) (loses)
1 Earnings per share (Adjusted to exclude exceptional items)
2 Net Profit (Adjusted to exclude exceptional items)
Current Analyst Recommendations & Revisions :
Buy : 2 Analyst
Outperform: 2 Analyst
